 |
   
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. News Ranbaxy, GlaxoSmithKline Settle Dispute Over U.S. Patent Covering ValtrexJuly 26, 2007 Under an agreement announced today, Indian pharmaceutical company Ranbaxy Laboratories Inc. will be allowed to introduce generic copies of the herpes drug Valtrex in the United States in the latter half of 2009. Ranbaxy will have 180 days of exclusivity to sell the pill here. The arrangement between Ranbaxy and GlaxoSmithKline PLC clears the way for the British drug company to drop the suit it filed in 2003 in a US court to stop Ranbaxy from selling generic copies of Valtrex. GSK's patent on Valtrex is due to expire in the United States and most European countries in 2009. In February, the US Food and Drug Administration approved Ranbaxy's plan to make and market generic Valtrex. Associated Press 07.26.2007  This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
|
|
Email
Print-Friendly
Glossary
The Body: About The Body | Contact The Body | Content Policy | Content Providers | Advertise With Us | Site Map
Remedy Health Media: About Remedy Health Media | Contact Remedy Health Media | Terms of Use | Privacy Policy
The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.
